**Suppl 1.** Overview of studies on 18FDG-PET/CT in OAMZL, from 2010 to 2025

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Reference** | **Study type** | **Number of patients studied** | **Ocular sites for OAMZL** | **Key findings** |
| Zanni et al. (2012) [1] | Retrospective | 26 (OAMZL); 41 (total cohort of ocular adnexal lymphoma (OAL)) | Orbit, lacrimal gland, conjunctiva, eyelid | * 18FDG-PET/CT was positive in 50% of ocular adnexal marginal zone lymphomas (OAMZL), while CT was positive in 79% of OAMZL * In view of the very high sensitivity of MRI and/or CT in the detection of ocular lymphoma sites, especially conjunctival involvement, 18FDG-PET/CT imaging is not very useful for the diagnosis of ocular adnexal lesions |
| Nasser et al. (2014) [2] | Retrospective | 18 (total OAMZL patients that underwent 18FDG-PET/CT); 21 (total cohort of OAMZL) | Conjunctiva | * Only two of 18 patients who underwent whole body PET/CT imaging had hypermetabolic focus in the area of the conjunctival lesion |
| English and Sullivan (2015) [3] | Retrospective | 14 (OAMZL); 31 (total cohort of OAL) | Orbit, lacrimal gland, conjunctiva, eyelid, lacrimal drainage apparatus | * 18FDG-PET/CT is less sensitive than CT in detecting ocular adnexal lymphoproliferative disease |
| Thuro et al. (2017) [4] | Retrospective | 61 (OAMZL); 119 (total cohort of OAL) | Not specified | * More than one-third of patients with primary OAL had evidence of systemic involvement in 18FDG-PET/CT at initial diagnosis |
| Fujii et al. (2018) [5] | Retrospective | 2 (OAMZL); 9 (total cohort of OAMZL) | Orbit, conjunctiva | * Patient with orbital OAMZL had a downtrend in post-treatment 18FDG-PET/CT metabolic score after treatment, while the patient with conjunctiva OAMZL could not be detected by 18FDG-PET/CT * 18FDG-PET/CT is useful for evaluating the response of OAL to treatment (surgery, radiotherapy and chemotherapy) |
| Park et al. (2019) [6] | Retrospective | 50 (non-conjunctival OAMZL); 123 (total cohort of OAMZL) | Orbit, lacrimal gland, eyelid | * 50 out of 60 (83.3%) non-conjunctival OAMZL lesions were FDG-avid with mean ± standard deviation SUVmax of 4.8 ± 2.4 (range, 2.0-11.1) * Mean SUVmax of orbit was significantly higher than that of lacrimal gland or eyelid * 14% of primary OAMZL patients had extra-ocular involvement detected by 18FDG-PET/CT and were upstaged to stage IIE or IVE, suggesting that 18FDG-PET/CT should be performed for staging of non-conjunctival origin OAMZL to guide treatment |
| Wang et al. (2022) [7] | Retrospective | 70 | Orbit, lacrimal gland, conjunctiva | * 80% of the OAMZL patients were FDG-avid with a median SUVmax level of 4.65 ± 3.00 * 92.0% of the mass forming lesions showed FDG-avidity, while only 50.0% of the non-massive lesions had FDG-avidity * FDG-avidity was correlated with high Ki-67 score (>15%) in OAMZL, however, SUVmax was not correlated with the Ki-67 score * SUVmax of OAMZL orbit masses were significant elevated as compared to those of the conjunctiva and lacrimal gland * FDG-avid OAMZL cases were more likely to achieve complete remission (CR) (70.4% achieved CR) as compared to non-FDG-avid cases (30.8% achieved CR), while SUVmax was not correlated with tumor remission rate |

**References:**

1.Zanni M, Moulin-Romsee G, Servois V, Validire P, Bénamor M, Plancher C, et al. Value of 18FDG PET scan in staging of ocular adnexal lymphomas: a large single-center experience. Hematology. 2012 Mar;17(2):76–84.

2. Nasser QJ, Pfeiffer ML, Romaguera J, Fowler N, Debnam JM, Samaniego F, et al. Clinical value of magnetic resonance imaging and other baseline testing for conjunctival mucosa-associated lymphoid tissue lymphoma. Leuk Lymphoma. 2014 May;55(5):1013–7

3. English JF, Sullivan TJ. The Role of FDG-PET in the Diagnosis and Staging of Ocular Adnexal Lymphoproliferative Disease. Orbit. 2015;34(5):284–91.

4. Thuro BA, Ning J, Peng SA, Pace ST, Dudeja G, Ozgur O, et al. Rates of Positive Findings on Positron Emission Tomography and Bone Marrow Biopsy in Patients With Ocular Adnexal Lymphoma. Ophthalmic Plast Reconstr Surg. 2017;33(5):355–60.

5. Fujii H, Tanaka H, Nomoto Y, Harata N, Oota S, Isogai J, et al. Usefulness of 18F-FDG PET/CT for evaluating response of ocular adnexal lymphoma to treatment. Medicine (Baltimore). 2018 Apr;97(17):e0543.

6. Park HL, O JH, Park SY, Jung SE, Park G, Choi BO, et al. Role of F-18 FDG PET/CT in non-conjunctival origin ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphomas. EJNMMI Research. 2019 Nov 21;9(1):99.

7. Wang W, Ni X, Tang T, Wang J, Li Y, Song X. The role of 18F-FDG PET/CT in diagnosis and treatment evaluation for ocular adnexal mucosa-associated lymphoid tissue lymphoma. Br J Radiol. 2022 Feb 1;95(1130):20210635.